Developing as a noteworthy advance in the struggle against obesity, this medication is generating considerable buzz. It combines properties of two known GLP-1 binding agonists, dulaglutide , and an additional glucose-dependent peptide component. Initial study findings have shown impressive body loss in individuals with a high BMI , possibly provid